- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03009214 | A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours | completed | Phase 1 | 55 | amcure GmbHINDUSTRY | 2 | May 10, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT01765790 |
| Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors |
| completed |
| Phase 1 |
| 68 |
| Baxalta now part of ShireINDUSTRY |
| 2 |
| May 5, 2021 |
| clinicaltrials |
| NCT04864379 | Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors | unknown | Phase 1 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04758897 | Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 18 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04455958 | Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Apr 26, 2021 | clinicaltrials |
| NCT04439214 | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01554371 | Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 44 | University of California, San FranciscoOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03721679 | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | terminated | Phase 1 / Phase 2 | 7 | Oncovir, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02152943 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02902237 | tTF-NGR Phase I Study | completed | Phase 1 | 24 | University Hospital MuensterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04226066 | Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 69 | Tasly Tianjin Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 7, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT01151930 | Long-Term Compassionate Use Study for Continued Administration of SCB01A-01 | no longer available | — | — | SynCore Biotechnology Co., Ltd.INDUSTRY | 0 | Nov 17, 2020 | clinicaltrials |
| NCT03512340 | Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers | completed | Phase 1 | 148 | Surface OncologyINDUSTRY | 2 | Oct 20, 2020 | clinicaltrials |
| NCT00836888 | ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan | completed | Phase 1 | 17 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03553108 | A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.(IVIVC) | completed | Phase 1 | 18 | AstraZenecaINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT02857920 | Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 45 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT02323191 | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | completed | Phase 1 | 221 | Hoffmann-La RocheINDUSTRY | 4 | Aug 27, 2020 | clinicaltrials |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT02843204 | Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 110 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04126668 | A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers | completed | Phase 1 | 24 | AnewPharmaINDUSTRY | 1 | May 21, 2020 | clinicaltrials |
| NCT02174172 | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 158 | Hoffmann-La RocheINDUSTRY | 2 | May 12, 2020 | clinicaltrials |
| NCT01435096 | BN80927 in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 56 | IpsenINDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT04275050 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 19, 2020 | clinicaltrials |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2020 | clinicaltrials |
| NCT04248348 | Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients(MeTHOS) | unknown | — | 600 | Metaxa HospitalOTHER | 1 | Jan 30, 2020 | clinicaltrials |
| NCT02518958 | A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab(PRIMETIME) | completed | Phase 1 | 12 | EpicentRx, Inc.INDUSTRY | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01606748 | A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin | completed | Phase 2 | 35 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02853903 | Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors | completed | Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT04076137 | Targeted T-cell Therapy in Solid Tumors | unknown | Early Phase 1 | 10 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01648764 | A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | completed | Phase 1 | 73 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 17, 2019 | clinicaltrials |
| NCT02045095 | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | terminated | Phase 1 | 29 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT02844400 | Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation | completed | — | 67 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT01858155 | Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors | completed | Phase 1 | 9 | C17 CouncilOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT03618043 | Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer | unknown | Phase 1 | 14 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT01128842 | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | completed | Phase 1 | 7 | Puma Biotechnology, Inc.INDUSTRY | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00768469 | Study Evaluating Safety And Tolerability, Solid Tumor | completed | Phase 1 | 10 | Puma Biotechnology, Inc.INDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00997360 | Study of PKI-179 Administered Orally to Subjects With Solid Tumors | withdrawn | Phase 1 | 0 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Sep 27, 2018 | clinicaltrials |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | completed | Phase 1 / Phase 2 | 110 | Puma Biotechnology, Inc.INDUSTRY | 9 | Jul 26, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT00958724 | Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors | completed | Phase 1 | 6 | Puma Biotechnology, Inc.INDUSTRY | 1 | Jun 28, 2018 | clinicaltrials |
| NCT01820299 | Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer | completed | Phase 1 | 22 | Medical University of South CarolinaOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT02786628 | Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation | completed | — | 43 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT03311100 | Immunological Profile of Solid Tumors Sample | unknown | — | 1,040 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT01519817 | Cancer Vaccine Targeting Brachyury Protein in Tumors | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2018 | clinicaltrials |
Data updated 22 days agoSource updated May 10, 2021source: clinicaltrials